Librela for Dogs: How It Works, Side Effects & the Safety Debate

What Librela Is and How It Works

Librela is the brand name for bedinvetmab, a monoclonal antibody approved by the FDA in May 2023 for the control of osteoarthritis pain in dogs. It is given as a subcutaneous injection roughly once a month, by your vet. There is no tablet and nothing for an owner to dose at home.

It works differently from an anti-inflammatory. Rather than reducing inflammation in the joint, it binds and neutralises nerve growth factor (NGF), a protein involved in transmitting pain. Because it is not processed by the liver or kidneys the way an NSAID is, it is often reached for in older dogs whose bloodwork makes long-term NSAIDs such as carprofen or meloxicam less attractive. That is a genuine advantage and part of why it became popular quickly.

The Safety Debate, With the Numbers on Both Sides

This is the part most pages either skip or sensationalise. Two bodies of evidence exist and they point in different directions.

The scale argument. Manufacturer pharmacovigilance covering 18,102,535 doses distributed between February 2021 and June 2024 recorded 17,162 adverse events — a rate of 9.48 per 10,000 doses. On that analysis the most common signs are "rare" and the rest "very rare", with lack of effect the single most reported outcome. Most dogs given Librela have no problem at all, and that is not spin — it is what 18 million doses show.

The signal argument. The FDA issued a Dear Veterinarian Letter about adverse events reported in treated dogs, covering neurological signs including ataxia, seizures, paresis and recumbency, plus urinary incontinence and increased thirst and urination. In some reports the outcome was death or euthanasia. By April 2024 the FDA's database held 3,674 reports involving Librela.

Both can be true. A rate of 9.5 per 10,000 is low; against 18 million doses it still means thousands of affected dogs. And adverse event reporting is passive — events are reported voluntarily, so the true rate is higher than the reported one by an unknown margin. A low reporting rate is reassurance about the odds for your dog. It is not evidence that the reports are mistaken.

When Side Effects Appear: the First Week Matters Most

The timing pattern in the FDA's review is unusually clear, and it is the most practically useful thing an owner can know. About two-thirds of reports described signs beginning within the first week of an injection, and roughly 30% within the first day. In 70% of cases the signs followed the first dose. If your dog is going to react, it will most likely be soon and after the first injection — so plan to watch closely that week rather than assuming trouble builds slowly over months.

What to Watch For

• • Wobbliness or loss of coordination — particularly in the back end
• • Weakness, difficulty rising, or inability to stand
• • Seizures
• • New urinary incontinence
• • Marked increase in thirst and urination
• • A sudden worsening of lameness rather than the improvement you were expecting

The difficulty is that an arthritic senior dog may already be stiff, slow to rise and occasionally unsteady. What matters is change — and specifically change that starts in the days after an injection. Report anything of this kind to your vet rather than waiting for the next monthly appointment, and ask them to file an adverse event report; that reporting is what the safety picture is built from.

Rapidly Progressive Osteoarthritis: the Unresolved Question

NGF does more than carry pain signals. It has roles in bone remodelling and cartilage maintenance — processes that are already working hard in an arthritic joint. Blocking it has been linked, in humans, rodents and rabbits, to rapidly progressive osteoarthritis: a joint deteriorating far faster than expected, sometimes to collapse or fracture.

This is not a fringe concern. It is the reason anti-NGF antibodies for humans did not reach approval, while the canine version did. A 2026 paper in JAVMA argues the same phenomenon deserves closer attention in dogs and more vigilant reporting. It appears to be uncommon — but unlike most drug reactions it is not reversible by stopping the drug. That asymmetry is worth weighing in the conversation with your vet, particularly for a younger dog facing years of treatment.

How to Think About the Decision

Untreated arthritis pain is not a neutral baseline — it costs a dog mobility, sleep and quality of life, and it is the reason many are eventually euthanised. Librela helps a great many dogs, and for one that cannot tolerate NSAIDs the alternatives narrow quickly. The useful questions are not "is it safe" but: how bad is the pain now, what else has been tried, does this dog have existing neurological signs, and how closely can you watch the week after the first injection. Those are answerable. A blanket verdict on the drug is not.

Frequently Asked Questions

Sources

• FDA — Dear Veterinarian Letter on adverse events reported with Librela
• Global pharmacovigilance reporting for bedinvetmab (PMC12061024)
• Bedinvetmab raises safety concerns including rapidly progressive osteoarthritis, JAVMA 2026 (PubMed 42361372)
• AVMA — FDA: Adverse events in dogs reported with monoclonal antibody drug